Group items tagged

The Royal Pharmaceutical Society (RPS) Scotland has launched an online pharmacy best practice hub to showcase the best practices adopted by pharmacy teams in Scotland. The brand new pharmacy best practice hub, hosted on the RPS Scotland website, went live on Thursday (August 11). RPS Scotland said: "Pharmacy teams across Scotland are undertaking fantastic work right now, in a variety of settings including community, hospital and general practice pharmacy as well as specialist settings. Many of these examples demonstrate the very best in pharmacy practice, which is supporting the profession to move further towards RPS Scotland's professional vision for the future of pharmacy, Pharmacy 2030." RPS wants to celebrate and share these examples with healthcare professionals, government, politicians, the public and potential pharmacy students to inspire people into the profession. It also provides a fantastic opportunity for pharmacy teams to share their practice with each other across the country.

The Royal Pharmaceutical Society (RPS) has appointed Laura Wilson as Director for Scotland commencing 23rd January 2023. Laura, is currently Policy and Practice Lead for RPS in Scotland. She is accountable for bringing national RPS policy to life for members in Scotland, while contributing to the GB wide professional leadership agenda. She will work closely with the Scottish Pharmacy Board, senior NHS officials and other key stakeholders across the breadth of the pharmacy profession and beyond to ensure pharmacy is on the forefront of healthcare in Scotland. She joins the existing team of RPS Country Directors, which includes Elen Jones, Director for Wales and James Davies, Director for England and will report directly to the Chief Executive. Laura Wilson said: "I am delighted to be appointed Director for Scotland having worked as part of the RPS Scotland team as the policy and practice lead. It will be an honour to continue the fantastic work started by former Director Clare Morrison to bring Pharmacy 2030, our vision for pharmacy in Scotland in the future, to life and supporting pharmacy teams to deliver person centred care.

Laura Wilson, Director of the Royal Pharmaceutical Society (RPS) in Scotland discussed the future of the pharmacy workforce with Michael Matheson, Cabinet Secretary for Health and Social Care at the SNP conference. The event, which took place on 17 October in Aberdeen, Scotland featured other health officials including Colin Poolman, Director of the Royal College of Nursing; Kenryck Lloyd-Jones, Public Affairs and Policy Manager for Scotland, Chartered Society of Physiotherapy; and Chris Marshall, Deputy Editor at Holyrood Communications. The Scottish government has recently unveiled its national workforce strategy for health and social care, laying out its plans for achieving recovery, growth, and transformation. Wilson highlighted the challenges and opportunities for the pharmacy workforce in Scotland to attract potential pharmacists into the profession and encourage them to stay within the profession. "This was a great opportunity to discuss with the Cabinet Secretary the challenges which exist for the pharmacy workforce in Scotland and to highlight some of the solutions which need to be implemented to ensure a pharmacy workforce in Scotland which is fit for the future," she said.

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

Acknowledging publication of the Royal Pharmaceutical Society (RPS) Scotland's new professional vision for the future of pharmacy in Scotland - Pharmacy 2030, a Parliamentary Motion has been lodged in the Scottish Parliament. The vision, produced in collaboration with the National Pharmacy Technician Group Scotland, expects all pharmacists in a patient-facing role to become independent prescribers by 2030. The motion recognised the aim of the publication that by 2030 pharmacy teams will work together, using their expertise to make the best use of medicines and, will take a person-centred approach, providing care holistically rather than by clinical condition. It highlighted the important role that RPS would play by working with partners across health and social care to turn this vision into a reality.

Professor Harry McQuillan has said community pharmacists in the UK must change their focus from an 'accuracy of supply' to a 'safety of supply' model when it comes to dealing with patients. "The main take away message from tonight's lecture is for pharmacy professionals to really challenge themselves about whether they are focused on accuracy of supply or safety of supply," he said at this year's UCL School of Pharmacy Lecture in London on Thursday, 15 June. "For our community pharmacists it must be about safety, including prescribing, and ensuring patients and citizens get the maximum benefit from prescribed medicines. "To deliver this, we need to invest in our teams - harness technology and always be willing to take the next step in a more clinical future." The Chief Executive Office of Community Pharmacy Scotland, however, noted that at a time when the UK was grappling with an unprecedented national debt crisis exacerbated by severe cost of living and spiraling inflation, community pharmacy will need to make a "compelling case" of where the priority should be in the sector. Expanding on the financial woes of the country, he compared the current national debt of the UK, which stood at a staggering 270 percent of GDP in September 2022, with the previous record-breaking national debt of 250 per cent at the end of WWII.

Chief executive of the Pharmaceutical Services Negotiating Committee Janet Morrison has said government ministers are looking at the future of community pharmacy in England in a "bigger way" and have a vision to go "beyond the Scotland model". "I think they believe they're going beyond the Scotland model," she said, in her closing keynote at the 7th Annual Pharmacy Business Conference held in London on Sunday (May 14). Giving her views on the latest government funding - worth £645 million - for community pharmacy, the head of pharmacy negotiator, added: "Their thinking is for the future in a bigger and a more forward-thinking way." She added it was for the first time that community pharmacy has been seen "as part of primary care in a really fundamental way that gives us hope for the future". Morrison said the new funding uplift was effectively "for five quarters of activity," arguing that the common condition service won't start before December or early in the New Year due to the time it would take to get the IT systems up and running to support the rollout.

The UK Commission on Pharmacy Professional Leadership set up by the Chief Pharmaceutical Officers of England, Northern Ireland, Scotland and Wales has published its recommendations for the 'future of pharmacy professional leadership in the UK' on Monday (6 February). The Commission is co-chaired by Nigel Clarke, Former Chair of the General Pharmaceutical Council, and Professor Dame Jane Dacre, Professor of Medical Education at University College London Medical School. The Commission proposes that closer collaboration between professional leadership bodies and specialist professional groups as part of a Pharmacy Leadership Council will enable and support pharmacists and pharmacy technicians to meet the opportunities and challenges ahead. The Council will be set up in 2023 to lead the implementation of the report's vision and recommendations over five years. Commission Co-Chairs, Professor Dame Jane Dacre and Nigel Clarke: "The Commission has set out a collaborative approach to transform pharmacy professional leadership and deliver sustained benefits for patients and the public and pharmacy professionals in the UK.

A new report commissioned by the National Pharmacy Association (NPA) has revealed harsh financial realities faced by community pharmacies in England. The report by Professor David Taylor of University College London warned that 1000s of community pharmacy closure might take place by 2024 in England if the sector was not supported with additional funds. At the launch of the report titled 'Protecting UK Public Interests in NHS Community Pharmacy', Prof Taylor said: "There will be several 1,000s of closures over the next few years unless we take appropriate action, which doesn't mean to pour money all over it, but it is to fund appropriately when necessary. "At the moment, if we got a partial collapse in the pharmacy network it would disrupt medicine supply and increase health inequalities… For me, it's missing out on the future development of better and more accessible care, which would be the tragedy of reducing, harming and damaging the pharmacy network unnecessarily."

The Royal Pharmaceutical Society (RPS) has confirmed it will respond to UK Commission's 'call for evidence' on pharmacy professional leadership. The commission wants to ensure the professions are well equipped, with a voice to help shape the future, and enabled to develop through sharing and learning from best practice. The UK Commission on Pharmacy Professional Leadership has been set up by the chief pharmaceutical officers of England, Scotland, Wales and Northern Ireland. It will produce recommendations for the future of pharmacy professional leadership in the UK. The commission is co-chaired by Nigel Clarke, former chair of the General Pharmaceutical Council, and Professor Dame Jane Dacre, professor of medical education at University College London's Medical School. The commission will be hosting a webinar and has urged the associations and individuals to take part in 'call for evidence' which has been launched to inform and develop its work. A webinar in England will take place on Wednesday 7 September 6:30 - 8 pm. In Scotland it will be organised on Tuesday 6 September 7-8:30 pm and in Wales it will be hosted on Thursday 8 September 7-8:30 pm.

Jonathan Burton will receive the 2022 RPS Charter Award for his outstanding work for the Society and the wider profession in promoting the interests of pharmacy. The award will be presented by the President at a future meeting of Fellows and Members to take place at the Society's Edinburgh office on 22nd March 2023. Jonathan's main role is as a practising, patient-facing pharmacist within the community in NHS Forth Valley where he uses his advanced practice skills and independent prescribing qualification to assess and treat acute ENT, dermatology, and respiratory conditions. He was one of the first community pharmacist prescribers in Scotland and has always been at the forefront of innovation and service development. Jonathan has demonstrated outstanding commitment and passion for the pharmacy profession throughout his career. He has excelled as a pharmacist in the Right Medicine Pharmacy group, on local and national committees, in advocacy for the pharmacy profession and as a local and national leader who is highly regarded as an exceptional role model for the profession.

Paul Rees MBE has joined the National Pharmacy Association (NPA) today (27 November) as its new Chief Executive. Current NPA Chief Executive Mark Lyonette, who is retiring, will remain at the NPA for some weeks in order to ensure a smooth handover. Previously, Paul has worked as the Chief Executive of the Royal College of Psychiatrists for the seven years. On joining NPA, Paul said: "It is a great privilege and honour to take up the position of NPA Chief Executive. The association is the voice of independent community pharmacy and is core to the sector's future success in England, Scotland, Wales and Northern Ireland. "I am delighted that the NPA has placed its trust in me and I intend to deliver for NPA members, for the sector and for society at large, which relies on there being a vibrant community pharmacy network in villages, towns and cities across the four nations of the UK." When Paul's appointment was first announced in September, NPA Chair Nick Kaye said that they identified him as an "excellent fit for our organisation" after a rigorous recruitment process, and also thanked Mark for his "great work as chief exec since 2018."

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

The Department of Health and Social Care (DHSC) launched a new Innovative Medicines Fund on Tuesday (June 7) under which £340 million has been made available to purchase potentially life-saving drugs early. This will allow NHS patients in England to have early access to potentially life-saving and cutting-edge treatments Health secretary Sajid Javid said: "I want NHS patients to be the first in the world to access the most promising and revolutionary treatments that could extend or save their lives. "The launch of the Innovative Medicines Fund delivers another manifesto pledge and will fast-track cutting-edge medicines to adults and children to give people renewed hope for a better future." A total of £680 million has been ringfenced for the Innovative Medicines Fund and Cancer Drugs Fund - £340 million each - to fast-track medicines to NHS patients. DHSC said: "The Innovative Medicines Fund will provide quick access to novel treatments, including potentially lifesaving gene therapies for serious conditions with few treatment options. It often takes longer for pharmaceutical companies to collect data on a medicine's clinical and cost effectiveness for rare diseases due to the smaller patient cohort.

As the population continues to age, the number of dementia cases in the UK could increase to rise to 1.5 million by 2040, a new study has predicted. The study report from Future Health also cautioned that over half a million people with dementia could remain undiagnosed by 2040, representing an increase of nearly a quarter of a million compared to the current figure, if there is "no progress in improving diagnosis rates." At present, approximately 850,000 individuals in the UK are living with dementia, with an estimated 315,000 cases going undiagnosed. Sponsored by Lilly, the study also highlighted significant variations in diagnosis rates across the four nations. Despite improvements, England's dementia diagnosis rate stands at 64.6 per cent, falling short of the two-thirds target.